Key result
Organized screening and HPV vaccination linked to ~3% annual decline in cervical cancer mortality.
Why the study?
Despite drops in cervical cancer rates following screening and HPV vaccination, regional variations and recent epidemiological changes indicate a need to review long-term trends and prevention effectiveness in high-income areas.
How have organized screening programs and HPV vaccines impacted cervical cancer incidence and mortality in high-income countries from 1990 to 2023?
Observational
Yes
How have organized screening programs and HPV vaccines impacted cervical cancer incidence and mortality in high-income countries from 1990 to 2023?
High-income countries have seen significant declines in cervical cancer mortality and incidence following the implementation of screening and HPV vaccination, though regional disparities persist.
Answers are grounded in this paper and cite their sources.
May support sustained HPV prevention programs; observational review leaves open drivers of regional disparities.
e17532 Background: Cervical cancer rates and deaths have dropped significantly in high-income countries after the start of organized screening programs and the rollout of human papillomavirus (HPV) vaccines. Still, the impact of the disease varies by region. Recent changes in epidemiology indicate a need to review long-term trends and the effectiveness of prevention efforts in these areas. Methods: We looked at data from the Global Burden of Disease (GBD) 2023 study for 59 high-income countries and territories (sociodemographic index greater than 0.80). We focused on outcomes such as incidence, mortality, disability-adjusted life years (DALYs), and age-standardized rates. We divided the analyses by age (15–49 years, 50 years and older) and by time period: pre-vaccination (1990–2006), early vaccination (2007–2015), and widespread vaccination (2016–2023). We used joinpoint regression to assess trends over time and to find significant changes. Results: In 2023, high-income regions reported about 45,200 to 52,800 new cervical cancer cases. This accounted for 12.8% of global cases, even though these regions only make up 16% of the global female population. Age-standardized incidence rates were between 6.2 and 7.8 per 100,000, showing significant regional differences. Nordic countries had the lowest rates at 3.1 to 3.8 per 100,000, while Central and Eastern Europe had rates more than double that, highlighting gaps in HPV vaccine coverage and screening access. Annual deaths ranged from 13,500 to 15,900. Age-standardized mortality rates declined by an average of 2.8% per year since 1990, which is a greater decline than the global average. Cervical cancer caused 485,000 to 612,000 DALYs, with nearly three-quarters due to early deaths. Incidence fell slightly before vaccination began, increased after the introduction of vaccines, and showed the steepest decrease after 2016 as vaccinated groups moved into higher-risk age ranges. Conclusions: High-income countries have made significant strides in reducing the burden of cervical cancer. However, major differences remain across regions and populations. Improving HPV vaccine uptake, expanding primary HPV-based screening, and enhancing access for underserved groups are crucial steps toward eliminating cervical cancer.
No takes yet. Share an insight, caveat, or question.
Balogun et al. (2026) conducted an observational in Cervical cancer. Organized screening programs and HPV vaccination vs. Pre-vaccination period (1990-2006) was evaluated on Incidence, mortality, disability-adjusted life years (DALYs), and age-standardized rates. Organized screening and HPV vaccination in high-income countries were associated with an average 2.8% annual decline in cervical cancer mortality since 1990.
Synapse has enriched 10 related papers. Consider them for comparative context: